Podcasts about silica

Miksi Suomi menee mukaan USA:n johtamaan Pax Silica -tekoälyliittoumaan, vaikka EU ei ole vielä tehnyt siitä päätöstä? Haastattelussa Teknologiateollisuuden johtava asiantuntija Joonas Mikkilä. Mikkilä pitää hyvänä, että Suomi lähti mukaan Pax Silicaan, koska yritykset voivat hyötyä siitä, mutta myöntää, että siihen liittyy myös riskejä. Riskinä voi olla USA:n sitoutumisen heikkeneminen Pax Silica -yhteistyöhön pitkällä aikavälillä, tai EU-linjan hajoaminen. Aloitteen epäselvä sisältö herättää Euroopassa epäluuloja. Yhdysvaltain presidentti Donald Trump ei herätä kaikissa suurta luottamusta, koska hänen toimintaansa pidetään arvaamattomana. Suomi ja Ruotsi ovat kuitenkin jo allekirjoittaneet Pax Silica -aloitteen, mutta esimerkiksi Ranska on vastustanut sitä. Hollannin esimerkki voi olla varoittava. Hollannissa toimiva kiinalaisomisteinen siruyhtiö Nexperia joutui Yhdysvaltojen vientirajoitusten piiriin. Kun Hollannin hallitus yritti ratkaista tilanteen ottamalla Nexperian valtion ohjaukseen, Kiina vastasi omilla siruvientirajoituksillaan. Voiko Suomi joutua myös vastaavaan tilanteeseen USA:n ja Kiinan välissä? Toimittajana on Linda Pelkonen.

The U.S. State Department's Pax Silica initiative reframes Pax Americana for the AI age — chips, semiconductors, critical minerals, energy, data centers, payment rails. This week in Beijing, two of the Trilogy of Boards Patrick Wood predicted clicked into place. The Trilogy is now whole. In this two-and-a-half-hour conversation, Courtenay Turner and Patrick Wood — co-authors of The Final Betrayal: How Technocracy Destroyed America — walk the architecture being built around you: Pax Silica, the IMEC corridor, the Abraham Accords as the template for the China play, the Five Walls boxing China in, Gaza's new order under the Board of Peace, Taiwan as silicon shield and silicon hostage, the tokenization of property and the New York Stock Exchange, the occult roots of the technocratic movement, and how to think about preserving sovereignty, autonomy, and property in a rapidly closing system. Read the full essay: https://courtenayturner.substack.com/p/pax-silica ━━━━━━━━━━━━━━━━━━━━ CHAPTERS ━━━━━━━━━━━━━━━━━━━━ 0:00 — Opening: The Petrodollar Ends, Pax Silica Begins 1:31 — Welcome to the Technocracy Roundtable 5:11 — Property, Rights, and the Founders' Distinction 6:44 — What Is Pax Silica? (Video Explainer) 9:08 — Locke, Private Property, and Sovereign Property 13:05 — The Regime That Comes With Tokenized Property 14:01 — Tokenization, Titles, and the Loss of Control 21:57 — When Your Home Becomes a Programmable Asset 24:58 — Sovereign Farm Rights and Self-Sufficiency 25:54 — Daniel's Silicon Kingdom: The Biblical Frame 29:22 — The State Department Pax Silica Declaration 30:45 — The Allies Joining the Corridor 34:29 — Terms-of-Service Control of Everything 39:05 — Why Technocratic Countries Rise to the Top 41:53 — Trump's Empire Strategy in Beijing 46:33 — How China Gets Boxed In: The Five Walls 51:46 — Global Power Shifts: BRICS, Gulf, India 58:18 — The Trump-Xi Meeting: Body Language and Substance 1:01:31 — Abraham Accords as the Template for China 1:06:54 — Israel, Zionism, and the Technocracy Conflation 1:11:56 — Gaza's New Order: USD1, CENTCOM, and the Board of Peace 1:15:13 — Gulf Sovereign Wealth, Islamic Finance, and Tokenization 1:25:32 — Pax Silica's New Power Triangle 1:37:53 — Taiwan and the Chip Leverage Question 1:45:02 — How the Trade Boards Replace the Global Order 1:52:25 — Why Technocracy Is Beyond Politics 1:56:04 — Occult Roots, AI Consciousness, and the 2025 Conclave 2:05:21 — HOAs as Control Layers 2:08:40 — Tokenization and the Financial Fallout 2:13:19 — Protecting Assets: Cash, Land Patents, UCC Article 8 2:30:00 — Closing: "Use AI to Destroy AI" ━━━━━━━━━━━━━━━━━━━━ KEY NUMBERS & SOURCES MENTIONED ━━━━━━━━━━━━━━━━━━━━ • New York Stock Exchange (ICE): $25 trillion in U.S. assets targeted for tokenization by end of 2026; $170 trillion globally • UN Security Council Resolution 2803: Board of Peace authorized November 17, 2025 • Trump-Xi Beijing summit: Boards of Trade and Investment agreed May 14, 2026 • Pax Silica Declaration: signed in Washington, December 12, 2025 • H.R. 3633 / Digital Asset Market CLARITY Act: passed July 17, 2025 by 294–134 ━━━━━━━━━━━━━━━━━━━━ FURTHER READING ━━━━━━━━━━━━━━━━━━━━ • Courtenay Turner & Patrick Wood, The Final Betrayal: How Technocracy Destroyed America • Patrick Wood, The New Economics of Technocracy • Patrick Wood, "The China Card: Global Technocracy Is Emerging Under Trump's Reign" • Courtenay Turner, "The Tokenization of Everything" • Courtenay Turner, "The Governance Stack: How Technocracy Was Built Over 200 Years" • Henry Kissinger, Eric Schmidt & Craig Mundie, Genesis: Artificial Intelligence, Hope, and the Human Spirit ━━━━━━━━━━━━━━━━━━━━ CONNECT ━━━━━━━━━━━━━━━━━━━━ Courtenay Turner: • Substack • Website • X: @CourtenayTurner Patrick Wood: • Technocracy.News • X: @StopTechnocracy ━━━━━━━━━━━━━━━━━━━━ The Final Betrayal: How Technocracy Destroyed America — co-authored by Courtenay Turner & Patrick Wood. Available through Coherent Publishing. #PaxSilica #Technocracy #Tokenization #PatrickWood #CourtenayTurner #TheFinalBetrayal #IMEC #CLARITYAct #Geopolitics #BeijingSummit Learn more about your ad choices. Visit megaphone.fm/adchoices

Securing AI dominance requires more than just semiconductors; it demands a complete overhaul of how the West manages everything that goes into them, from rare earth minerals to actuators. Enter: Pax Silica. Sarah Guo and Elad Gil sit down with US Under Secretary of State for Economic Affairs Jacob Helberg to discuss the launch and expansion of Pax Silica, a 14-country economic security coalition designed to secure the entire AI supply chain. Jacob talks about the creation of a forward-deployed industrial base in the Philippines, where 4,000 acres will be developed into an “economic security zone.” He also compares and contrasts Pax Silica with China's Belt and Road initiative, explains how the US plans to reindustrialize through automation and robotics, and explores how the Trump administration envisions making these policies durable across future presidencies. Plus, we hear why Jacob believes America to be a “global underdog.” Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @jacobhelberg | @UnderSecE Chapters: 00:00 – Cold Open 00:41 – Jacob Helberg Introduction 01:02 – Pax Silica's Mission 03:51 – Investing in AI Chip Supply Chains 05:43 – Comparing Pax Silica to China's Belt and Road Initiative 12:38 – Pax Silica's Value Proposition 14:38 – US vs. Partnered Manufacturing 19:10 – Rare Earth Mineral Pricing 22:16 – Role of Venture Capital in Pax Silica 24:50 – Near vs. Long-Term Priorities 27:09 – Making AI Policy Durable 28:09 – How Policies Impact Entrepreneurs 31:00 – Trump's Entrepreneurial Administration 33:00 – Why America is a Global Underdog 38:00 – Conclusion

In this special episode of The kbbreview Podcast, host Andrew Davies speaks exclusively to Mike Calcutt, Deputy Director in the HSE's Engagement and Policy Division, about the regulator's major update to its guidance on engineered stone fabrication and silica dust exposure.With silicosis cases rising globally, and Australia already banning engineered stone outrigh, the UK industry is now facing tougher expectations around water suppression, mist extraction, respiratory protection and health surveillance.Calcutt explains why HSE believes there is now “no scope” for dry cutting engineered stone, how the regulator plans to inspect more than 1,000 workplaces over the coming months, and why the new guidance stops short of introducing a full ban on high-silica materials.We also discuss the responsibilities of fabricators, suppliers and kitchen retailers, the growing push towards lower-silica products, and whether this is the end of the debate or just the beginning... Hosted on Acast. See acast.com/privacy for more information.

OPINION: What Pax Silica is and why Bongbong keeps ceding PH territory | May 2, 2026Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribe Visit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcher Tune In: https://tmt.ph/tunein #TheManilaTimes #KeepUpWithTheTimes Hosted on Acast. See acast.com/privacy for more information.

Brian Leeners is the CEO/founder of Homerun Resources (HMR.V), a Brazilian-based silica company dedicated to bringing high-quality silica to market to help advance the solar, renewables, and AI growth initiatives. We spent the podcast discussing the solar value chain, silica's role within that chain, what makes silica different, the supply/demand dynamics of the market, and what separates Homerun Resources' asset from its peers. I learned a ton about silica and found a new interesting idea in the process. I hope you enjoy!PLEASE NOTE THAT NOTHING IS INVESTMENT ADVICE. DO YOUR OWN WORK. NOTHING IS ADVICE ON THIS PODCAST.

Every day, millions of workers around the world go to work knowing their job is hard. But no one should go to work knowing it might slowly take their breath away. Across the United States and Canada, USW members are on the front lines of the fight against silica dust exposure, pushing for stronger protections, enforcement of safety rules, and justice for workers who've already been harmed. We're talking with several activists who know this fight firsthand: Marshal Cummings, a USW safety leader working in the mining industry in Wyoming, and Sean Staddon, a compensation officer and member of USW Local 6500 in Sudbury, Canada. Their stories highlight why this fight is global and why the labor movement must keep pushing. Music in today's episode is by Ketsa.

Internet no vive en “la nube”.Vive en edificios llenos de servidores, calor, cables, discos, agua y consumo eléctrico. Y con la explosión de la inteligencia artificial, estamos llegando a un punto en el que guardar datos puede convertirse en uno de los grandes problemas técnicos y energéticos del siglo.Por eso ya hay científicos y empresas trabajando en algo increíble: grabar información dentro de cristal para conservarla durante miles de años.En este vídeo vas a ver:- el verdadero coste físico de Internet- por qué la IA está agravando el problema- cómo funciona el almacenamiento en vidrio- qué papel juega Microsoft en esta carrera- y por qué algunos creen que el futuro del archivo digital podría parecerse más a una piedra transparente que a un disco duroLa nube no flota.La nube pesa.Y quizá el futuro del almacenamiento no esté en un servidor más grande, sino en un cristal.

OPINION: How Pax Silica could multiply PH's economic risks | Apr. 27, 2026Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribe Visit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcher Tune In: https://tmt.ph/tunein #TheManilaTimes #KeepUpWithTheTimes Hosted on Acast. See acast.com/privacy for more information.

On this episode of Vitality Radio, Jared sits down with Jodi Sanders, National Educator for BioSil, to explore the science behind collagen production and why supporting your body's natural processes may be more effective than simply supplementing collagen alone. They break down the critical roles of collagen, elastin, and keratin in maintaining healthy hair, skin, nails, joints, and connective tissue—and why production declines with age. You'll learn how BioSil's patented choline-stabilized orthosilicic acid (CHOSA) is designed to support the body's natural collagen-building pathways, along with insights into lifestyle factors that impact these structural proteins. The conversation also introduces a new, highly digestible plant-based protein designed to deliver a complete amino acid profile. If you're looking to support healthy aging, structural integrity, and overall vitality, this episode delivers practical, science-backed insights.Products:Biosil Advanced Collagen GeneratorBiosil Daily Beauty ProteinAdditional Information:#542: VR Vintage: Your Collagen User's Guide: How to Preserve and Build Collagen NaturallyVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Weekly Goss – April 23, 2026Matt and Hamish are back from Adelaide to discuss the latest housing developments in Canberra, a major safety crackdown on silica dust, and the importance of representation in the trades.In This Episode:The Canberra Housing Deal: The ACT and Commonwealth governments have signed a $250 million deal to deliver 4,900 homes, with over 1,700 reserved for first-home buyers.The Rising Cost of Building: A look at the staggering 74% increase in building costs since 2009 and the impact of global events on the industry.Silica Safety Crackdown: South Australia is leading a massive compliance campaign targeting silica dust. Any material with more than 1% silica (including cement sheeting, bricks, and tiles) is under the microscope.Health & Prevention: Matt shares a personal story regarding silicosis and emphasises why tradespeople must prioritise using vacuums and wearing masks, even when under pressure.Design Responsibility: Why architects and designers should be conscious of the materials they specify to reduce on-site cutting risks.Women in Trades: A shout-out to Sophie (@sister.carpentry) on Instagram for her work in encouraging women to join the construction industry.Key Resources & Mentions:Guest Spotlight: Follow Sophie @sister.carpentry on Instagram.South Australia Hosts: Huge thanks to Climasure, Pro Clima, and Endurobuilders for hosting the team in SA.Alternative Products: Mention of Weathertex and magnesium board as safer cladding alternatives.Upcoming Events:SBA Retrofit Playbook (May 7th): Featuring experts like Sarah from Coogee and Dylan from Orlin Construction. Tickets are roughly $30–$40.Passive House Conference (June 25-26, Victoria): Matt and Hamish will be hosting a breakaway room for builders and architects.Promo Code: Use themindfulbuilder for 10% off your tickets

** VIDEO EN NUESTRO CANAL DE YOUTUBE **** https://youtube.com/live/OJzB7FkdMPc +++++ Hazte con nuestras camisetas en https://www.bhmshop.app +++++ ¿Estamos ante el verdadero plan estratégico de Estados Unidos contra China? No hablamos de una guerra abierta… sino de algo más sofisticado: desacoplamiento selectivo, control tecnológico y presión energética En este programa de ¿Hablamos? analizamos cómo Washington está redibujando el tablero global en 2026: Pax Silica: el control del silicio, los chips y la IA Derisking: ruptura parcial de cadenas de suministro críticas Indo-Pacífico: Indonesia, Filipinas y el cerco estratégico Taiwán: el corazón del poder tecnológico mundial Ormuz y energía: presión directa sobre el petróleo que alimenta a China 5G e IoT: la guerra invisible por el control de los datos y la infraestructura No es una guerra clásica. Es una guerra por el control del siglo XXI. Y como en toda gran estrategia, hay ventajas… pero también riesgos: inflación energética fragmentación global escalada geopolítica Porque hoy, el poder no solo se mide en ejércitos… se mide en chips, datos y energía. SUSCRÍBETE para no perderte ningún programa y únete a nuestra comunidad de apasionados por la historia militar, la geopolítica y los conflictos del mundo. Apóyanos para seguir creando contenido riguroso e independiente: Patreon: https://www.patreon.com/bellumartis PayPal: https://www.paypal.me/bellumartis Bizum: 656 778 825 Síguenos también en redes: Instagram: https://www.instagram.com/bellumartis Twitter / X: https://twitter.com/Bellumartis Bellumartis Historia Militar — Porque entender el pasado es prepararse para el futuro. #EEUUvsChina #Derisking #PaxSilica #Geopolítica #Ormuz #5G #IoT #Taiwán #Semiconductores #Energía #ActualidadMilitar #Bellumartis

Get my FREE ebook, ‘Rebalancing Your Hormones Naturally.' Actionable strategies for immediate results! 

Coming up this week on Pets Who Thrive. Homeopathic veterinarian Dr. Todd Cooney joins Tammy to discuss spaying and neutering and potential long-term health concerns increasingly linked to the procedure. Cooney also mentions using homeopathic remedies like Thuja and Silica to address potential vaccine-related chronic issues. It's all this week on Pets Who Thrive with Tammy King!

The America's Work Force Union Podcast tackles two of the most pressing issues facing the modern industrial landscape: the long-term health of construction workers and the strategic strength of our national defense. Segment 1: 10 Years of Silica Progress Lily Calderon, Health and Safety Director for the International Union of Bricklayers and Allied Craftworkers (BAC), joins us to mark the 10th anniversary of the OSHA silica rule. We discuss how the BAC turned a hidden hazard into a regulated standard, the importance of engineering controls like HEPA vacuums, and why "Table 1" guidance needs an update to reflect modern jobsite technology. Segment 2: Defense Capacity & The Skilled Labor Gap Retired IAM Union International President Tom Buffenbarger breaks down why massive defense budgets won't fix production shortages without a skilled workforce. We explore the erosion of the industrial base, the critical need for apprenticeships in precision machining, and how artificial intelligence is reshaping aerospace manufacturing and strategic planning.

EPISODE 41:In this episode, Dr. Rachel sits down with Jonathan Rickert and Jeff Lioons Jr. to dive deep into environmental toxicity, specifically the pervasive nature of aluminum and its impact on modern health. They explore how heavy metals act as a chronic, low-level depletion on the system, often staying hidden in the tissues even when conventional blood or hair tests show nothing.Together, they discuss the clinical utility of the OligoScan, a device that measures minerals and heavy metals directly in the tissue to provide a clearer picture of what the body is actually holding onto. The conversation highlights why so many practitioners and patients are confused by traditional testing and how a tissue-based approach reveals the startling reality: almost everyone scanned is high in aluminum.The episode breaks down the "why" behind this epidemic, from common household items like antiperspirants and aluminum cans to more direct routes like vaccinations and environmental chemtrails/geoengineering. Dr. Rachel and her guests also discuss the critical roles of silica, boron, and glycine in protecting the body's collagen and assisting in the safe, gentle excretion of these toxins.Closing with a message of hope, the guests share their approach to detoxification—not through harsh, depleting chelation, but by giving the body the essential minerals it needs to restore balance and "export" what doesn't belong.Highlights:The OligoScan Advantage: Why tissue testing may be more accurate than hair or blood for finding "hidden" toxins.The Aluminum Epidemic: Why almost every person scanned shows high levels and where it's coming from.Collagen & Glyphosate: How aluminum and glyphosate deplete the integrity of your body's "glue".The Power of Silica & Boron: Using targeted minerals to gently lower metal burdens without harsh chelation.Environmental Truths: Discussing aluminum levels in rainwater and snow, and the biological impact of environmental pollution.Sweat as Medicine: Why sweating is a vital route for metal excretion and what happens when that system is "stuck".The Copper/Zinc Balance: Navigating the nuances of copper toxicity vs. deficiency and how the nervous system plays a role.Aluminum Explort: The story behind the specialized formula created to support the body's natural detoxification pathways.About Jonathan Rickert and Jeff Lioons Jr.Jonathan Rickert and Jeff Lioons Jr. are health innovators and practitioners dedicated to uncovering the root causes of chronic depletion through advanced scanning and mineral therapy. Jeff has performed thousands of scans using the oligoscan, providing a massive clinical data set that informed the creation of Aluminum Export, a product designed to support the body's natural detoxification pathways of exporting aluminum. Jonathan Rickert is a pro‑metabolic nutritionist and mineral‑balancing specialist who helps other rebuild optimal cellular energy, and is the cofounder of Ionome Labs. Together they advocate for a "safer, gentler approach" to healing that prioritizes mineral replenishment and environmental awareness.Connect & Shop:Website: IonomeLabs.com (Use code _drrachel_ for 10% off)X: @IonomeLabsTikTok: @IonomeLabs

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Brendan O’Connell recounts his history as a political activist who faced imprisonment and censorship for investigating Israeli intelligence and high-technology contracts. He describes a global power struggle competing for control over humanity through advanced AI and data collection. O’Connell argues Israel functions as a primary hub for the technological infrastructure used for global surveillance, including quantum computing and AI. He rejects the likelihood of a third world war, viewing current geopolitical tensions as manufactured narratives designed to maintain public anxiety. He concludes by urging listeners to move beyond online discourse and engage in direct political lobbying of military and government agencies to reclaim sovereignty from these technocratic systems. Watch on BitChute / Brighteon / Rumble / Substack / YouTube *Support Geopolitics & Empire! Become a Member https://geopoliticsandempire.substack.com Donate https://geopoliticsandempire.com/donations Consult https://geopoliticsandempire.com/consultation **Listen Ad-Free for $4.99 a Month or $49.99 a Year! Apple Subscriptions https://podcasts.apple.com/us/podcast/geopolitics-empire/id1003465597 Supercast https://geopoliticsandempire.supercast.com ***Visit Our Affiliates & Sponsors! Above Phone https://abovephone.com/?above=geopolitics American Gold Exchange https://www.amergold.com/geopolitics easyDNS (15% off with GEOPOLITICS) https://easydns.com Escape The Technocracy (15% off with GEOPOLITICS) https://escapethetechnocracy.com/geopolitics Outbound Mexico https://outboundmx.com PassVult https://passvult.com Sociatates Civis https://societates-civis.com StartMail https://www.startmail.com/partner/?ref=ngu4nzr Wise Wolf Gold https://www.wolfpack.gold/?ref=geopolitics Websites YouTube https://www.youtube.com/@Talpiot_Program Substack https://substack.com/@brendonoconnell Patreon https://www.patreon.com/cw/talpiot *Podcast intro music used with permission is from the song “The Queens Jig” by the fantastic “Musicke & Mirth” from their album “Music for Two Lyra Viols”: http://musicke-mirth.de/en/recordings.html (available on iTunes or Amazon)

First, we talk to The Indian Express' Himashu Harsh about a ban that has been announced in Bihar. A ban on open-air and unlicensed meat sales has been announced in Bihar due to sanitary and health concerns. He shares what the ban entails, how it will be implemented and more.  Next, we talk to The Indian Express' Diplomatic Affairs Editor Shubhajit Roy about India's inclusion into the Pax Silica, which is a strategic technology pact that places India inside a US-led effort aimed at securing AI, semiconductor and critical technology supply chains among what Washington calls trusted partners. (8:40)Lastly, we talk about the an encounter in Jammu and Kashmir's Chatroo which killed three terrorists. (21:52)Hosted by Niharika NandaProduced by Niharika Nanda and Ichha Sharma Edited and mixed by Suresh Pawar

Pool Pros text questions hereIn this episode, Rudy Stankowitz discusses significant developments in the pool service industry, including a major acquisition that consolidates market power. He also delves into the importance of understanding water chemistry, specifically focusing on silica and sulfates, which are often overlooked in pool maintenance. The conversation highlights the implications of these elements on pool equipment and overall maintenance practices, emphasizing the need for pool professionals to adapt to these changes for better service delivery.takeawaysThe pool service industry is experiencing significant consolidation.Larger operators can invest in better technology and training.Silica and sulfates are critical yet often ignored in pool chemistry.Municipalities add silicates to drinking water to prevent corrosion.Silica fouling can lead to equipment inefficiencies.Sulfates can cause long-term damage to pool structures.Monitoring silica and sulfate levels is essential for pool maintenance.Dilution is the most effective way to manage silica and sulfate levels.Understanding water chemistry can prevent costly repairs.Advanced knowledge in pool chemistry is crucial for professionals.Sound Bites"Silica fouling increases electrical resistance.""Sulfate ions can react with calcium aluminate.""The ones that get paid a lot of money do."Chapters00:00Introduction and Industry Update04:33Water Chemistry: Silica and Sulfates Overview05:16Understanding Silica in Pool Water17:46Exploring Sulfates in Pool Water AquaStar Pool ProductsThe Global Leader in Safety, Dependability, & Innovation in Pool Technology.POOL MAGAZINE Pool Magazine is leading up to the minute news source for Swimming Pool News and Pool Features. Outhe 'How to Get Rid of Algae' handbookThe most comprehensive guide on algae prevention and remediation you will ever own. BLUERAY XLThe real mineral purifier! Reduce your pool maintenance costs & efforts by 50%CPO Certification ClassesAttend your CPO class with Rudy Stankowitz!Online Pool ClassesThe difference between you and your competition is what you know!Jack's MagicIf you know Jack's you'd have no stains!Service Industry NewsDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showThank you so much for listening! You can find us on social media: Facebook Instagram Tik Tok Email us: talkingpools@gmail.com

In this episode of IPS Finance, we examine why Novartis shares surged by 20% and the key factors behind this sharp rally. The discussion also covers how the Pax Silica – US–India agreement has created a positive impact on market sentiment and certain sectors. A crisp analysis to help investors understand the reasons behind the movement and what it could mean for future investment decisions.

WHAT YOU NEED TO KNOW?Paid Purchase Order: Management confirms the 50 kg fumed silica order is paid, with material produced and shipment logistics underway.Pilot Plant Function: The facility is performing its intended role — demonstrating scalable material production rather than prioritizing immediate revenue generation.Application Objectives: Management indicates that internal work and independent laboratory testing support that the material meets the goals for the intended application.Due Diligence Relevance: The batch is framed as a meaningful component of the technical due diligence process tied to a potential joint venture.Operational Data: Pilot plant runs are now informing more detailed assumptions, including practical considerations such as shifts, staffing, and location-dependent cost factors.Market Signaling: Management notes that milestones such as paid production runs may influence how other parties evaluate ongoing discussions.When a pilot plant progresses from demonstrating production capability to fulfilling a paid purchase order, the discussion naturally shifts from technical feasibility to real operating performance. HPQ Silicon management confirms the company has received a purchase order for 50 kilograms of fumed silica, has produced the material, and is now finalizing shipment logistics as the counterparty determines where the batch will be sent. Management explicitly states the order is paid, while underscoring an important distinction for investors: pilot plants are designed to validate commercial-scale production and generate operating data, not serve as near-term profit centers. The batch is described as part of the technical due diligence process associated with a potential joint venture, with management noting that successful material production is a necessary condition for advancing discussions. Internal testing and independent laboratory testing are described as supporting that the material meets the objectives required for the intended application.STRATEGIC IMPLICATIONSManagement emphasizes that pilot plants are not structured as profit-driven operations. Their purpose is to demonstrate that commercially valuable material can be produced and to provide the data required for designing larger-scale facilities. The discussion highlights that once systems are functioning, producing a single larger batch becomes more operationally efficient than multiple small runs. Management also indicates that a significant portion of current activity is concentrated on the joint venture process, describing both HPQ Silicon and its technical partner as heavily engaged in technical evaluation, operational analysis, and commercial discussions.INVESTOR TAKEAWAYThe significance of the paid 50 kg batch is primarily technical and strategic rather than financial. The milestone reflects pilot plant validation, supports customer-side application testing, and contributes to the refinement of detailed operating assumptions required for potential commercial expansion. As described by management, the project remains positioned within an active due-diligence phase rather than a finalized commercial rollout.

The same DOD team that called Silica a weaponization signature in anthrax found silica in civilian patients and called it dirt. Crystal says, "So here are the names, and here are their papers, the proof, and also ... happy 400th episode of More Morgellons, a podcast heard in over 100 countries worldwide, because ... ya know, global mass delusions lasts for over two decades and get bigger every year in spite of no media coverage and massive censorship."

When a company crosses the line from technical validation to signed commercial agreements with secured financing, markets take notice. HPQ Silicon has signed a non-binding memorandum of understanding with a strategic industrial partner to form a joint venture that would build and operate a 1,000-tonne-per-year commercial fumed silica plant valued at US$20.0 million. The partner has already secured project financing. This follows January 30, 2026 independent verification confirming HPQ's pilot-scale reactor produces commercial-grade "150" fumed silica. With the technical risk answered, now came the commercial deployment question which seems to now be answered with one breaking headline:HPQ Signs Joint Venture MOU for a Commercial Fumed Silica Plant with Strategic PartnerWHAT YOU NEED TO KNOWFinancing Secured: The strategic partner has already locked in project funding for the US$20.0 million commercial plant, eliminating a major execution risk.Grade 150 Verified: Independent testing on January 30, 2026 confirmed HPQ's pilot reactor produces commercial-grade fumed silica meeting industry-standard 150 m²/g surface area and required viscosity specifications.Toxic-Free Process: HPQ's plasma-based reactor eliminates silicon tetrachloride and hydrogen chloride - the hazardous chemicals that forced half the industry to relocate to China.Dramatic Cost Advantage: The single-step process consumes ~ 87% less energy and produces ~ 84% fewer emissions than conventional multi-step manufacturing while enabling on-site production.Q2 2026 Target: Definitive agreements are expected by the end of second quarter 2026, with plant delivery anticipated within 12 months of joint venture formation.Commercial Structure and Strategic IntentThe joint venture is expected to own and operate the facility, with production sold under an offtake arrangement to the strategic partner (terms and conditions yet to be agreed upon). Under the contemplated structure, HSPI (HPQ's wholly owned subsidiarywould receive recurring royalties on each kilogram of fumed silica sold, (price/kg not yet agreed upon), providing HSPI and HPQ with long-term exposure to operating revenues while maintaining a capital-efficient profile.HPQ does caution with “While the MOU reflects a shared intent to proceed, there can be no assurance that a joint venture will ultimately be formed, that it will be completed within the anticipated timeline, or that it will prove commercially viable.”STRATEGIC IMPLICATIONSFor decades, fumed silica manufacturing has relied on a toxic, multi-step process that converts metallurgical silicon into silicon tetrachloride, then hydrolyzes it at extreme temperatures while generating massive volumes of hydrogen chloride waste and CO₂ emissions. Environmental regulations pushed at least half of global production to China, creating supply chain vulnerabilities and locking manufacturers into centralized production models with complex logistics. What incumbents failed to achieve was elimination of the chemical inputs entirely - the breakthrough that enables decentralized, on-site manufacturing.This positions HPQ to redefine how manufacturers access a US$2.57 billion global market dominated by chemical giants who cannot easily replicate a process they don't control.CEO BERNARD TOURILLON:"This is the demonstration of all the work we've done paying off. We've demolished the barriers to entry to make fumed silica. Now we're building something solid, step by step. The fumed silica business is becoming a very strong standalone thing."For investors seeking exposure to advanced materials disruption with tangible proof points and near-term commercial deployment, this marks the inflection from development to deployment.

In today's episode on 11th Feb 2026, we tell you how China came to dominate the global critical mineral supply chain and the US' Pax Silica initiative that it believes can counter it.Book a free call with Ditto

My guest for this episode is Dr. Wendy Zellner.Dr. Zellner received her doctorate from the University of Toledo in 2012, where she trained in molecular and cellular biology with a focus on the role of silicon in plant defense responses. She then completed a four-year postdoctoral position with the USDA-ARS, continuing her research on how silicon can alleviate both abiotic and biotic stress in crops such as tomato and tobacco.Her work has included developing standard methods for quantifying silicon uptake from fertilizer materials, identifying uptake mechanisms for silicon in model species, and evaluating how those pathways function across a range of crop systems.In this conversation we cover:The role of silicon in plant physiology and structureSilicon and plant defense against abiotic and biotic stressHow plants take up and utilize siliconMisconceptions around silicon fertilizers and supplementsPractical considerations for growers using silicon inputsThis remains one of the most comprehensive discussions we've had on silicon and plant health, and it continues to be highly relevant for growers looking to better understand how this element functions within a complete fertility program. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What You Need To KnowIndependent third-party validation confirms commercial-grade 150 fumed silica produced at pilot scaleValidation performed by a potential customer under an existing Letter of IntentResults support ongoing commercialization discussions, including with the party under LOIPerformance metrics, including viscosity, meet or exceed benchmark specificationsPlanning initiated for a potential dedicated production site as demand visibility improvesHere's how HPQ Silicon Inc. is positioning its proprietary process as a simplified, lower-barrier alternative with the potential to materially change production economics in a legacy industrial materials market.Fumed silica is a critical additive used to control thickness and stability in products ranging from toothpaste and cosmetics to adhesives, coatings, inks, and advanced industrial formulations. Despite its broad use, the industry has relied for decades on complex, fossil-fuel-intensive, multi-step manufacturing processes that are costly, environmentally burdensome, and dominated by a small number of global suppliers.HPQ's approach is fundamentally different. Its process converts quartz directly into fumed silica in a single step, eliminating several traditional intermediates. The result is a simplified production pathway that has the potential to reduce complexity and materially alter the cost structure associated with fumed silica manufacturing.While HPQ had previously demonstrated promising lab-scale results, commercialization in industrial materials depends on more than internal testing. Customers must confirm that a product performs within their own application and process requirements.That hurdle has now been cleared.Independent testing conducted by a potential customer under LOI confirmed that HPQ's pilot-scale material meets commercial-grade 150 specifications, including surface area and viscosity—two of the most important performance metrics buyers evaluate.“Until we had gotten this result, we were making a big claim. Now, we have the data to prove it.” — Bernard Tourillon, CEO, HPQ Silicon Inc.Commercial-grade 150 is not an experimental specification. It is a sellable, widely used product grade in today's market. Importantly, HPQ's material demonstrated viscosity performance above standard benchmarks for the 150 grade, a key factor in real-world applications where fumed silica is purchased specifically for its thickening and rheological properties.With validation in hand, HPQ reports that commercialization discussions have continued in parallel, including dialogue around the steps required to move toward an initial commercial-scale facility. While execution of the first plant remains the primary remaining risk, management emphasized that the most difficult technical transition—moving from lab to pilot scale—has already been completed.The fumed silica initiative is supported by a joint operating structure with PyroGenesis Inc., combining HPQ's commercial strategy with PyroGenesis' engineering and process expertise. This structure is designed to reduce execution risk as the project advances toward continuous operation and commercial-scale deployment.With independent customer validation, a defined commercialization pathway, and early planning for a dedicated production site, HPQ has moved its fumed silica initiative into a new phase. The remaining challenge is execution—building and operating the first commercial system—but the company now approaches that step with verified performance data, active industrial engagement, and a clearer line of sight to market demand.For investors seeking small-cap opportunities where technical risk has been substantially reduced and commercialization discussions are grounded in disclosed customer validation, this interview captures a moment where HPQ's fumed silica strategy begins to transition from promise to potential production.

Send a text to Melissa and she'll answer it on the next episode. Let's talk honestly about constipation—what's truly normal, what's not, and how to get back to regular without relying on harsh laxatives. We break down the real signs of constipation beyond just “skipping days,” including hard, dry stools, straining, incomplete emptying, or no urge at all, and we map those patterns to targeted homeopathic remedies that support the body rather than forcing it.We walk through practical matches: Nux vomica for tense, irritable, stressed-out “always urging, never empty” patterns; Bryonia for dryness and pain that worsen with movement; Alumina when there's no urge and sluggish bowels; Silica for the “bashful stool” that slips back in; Opium for severe sluggishness after anesthesia or medications; Calc Carb for slow metabolism and large, painful stools, especially in kids; and Lycopodium for afternoon bloating, trapped gas, and IBS-like discomfort. Along the way, we share how to choose potencies and frequency with a light, sensible touch.Beyond remedies, we dig into the everyday shifts that make a big difference: choosing the right magnesium and pairing it with Mag phos, staying truly hydrated, using warm lemon water to prime digestion, and leaning on fruit like prunes, pears, kiwi, and berries. Movement matters more than most people realize, so we offer simple ideas—from walking to gentle squats—to nudge peristalsis. Parents will find guidance for easing fear and withholding in kids with kindness and flexible strategies.We also flag when to seek medical input: blood in stool, severe pain, more than five days without a bowel movement, unexplained weight loss, or recurring episodes. Most of all, we connect the dots between elimination and whole-body health—mood, skin, energy—so you can move from coping to confident. If this conversation helps, subscribe, share it with a friend who needs relief, and leave a quick review so more people can find these practical tools.You may also gain Access to my Fullscript dispensary and save 30% by going to: https://us.fullscript.com/welcome/mcrenshawFIND ME!

Michael McCall of Walsworth LLP, a law firm with four California locations, discusses what fabricators should know about regulation with silica.

The odds appear stacked against US President Donald Trump as over 70% traders are betting that the US Supreme Court will declare tariffs illegal. Telcos have approached TRAI over alleged monopolistic practices at Navi Mumbai international airport, where each of them is paying Rs 92 lakh per month. How entry in US-led Pax Silica can benefit India and a look at the finances of Mumbai as the municipal corporation goes to vote tomorrow – all this and much more in the latest Moneycontrol Editor's Picks. Tune in.

In this episode of Imperfect Show Finance, stock market expert V. Nagappan breaks down what happened during the crucial 45 minutes of today's trading session that changed the direction of the market. The discussion highlights the three key reasons behind the sudden rally, explaining how specific triggers, data points, and investor behavior combined to push indices higher. The episode also explores what the Pax Silica Alliance is and why it matters, along with updates on the much-awaited NSE IPO timeline. In addition, the conversation covers important developments related to Maruti, IOC, and the latest CPI data, helping viewers understand how company news and macroeconomic indicators are shaping market sentiment. Packed with timely insights and clear analysis, this video helps investors stay informed and make smarter decisions in fast-moving markets.

What You Need To Know• Commercial-grade fumed silica achieved at pilot scale, triggering inbound interest• New technology demand could push fumed silica beyond existing global capacity• UL 1642 cell-level certification opens U.S. battery commercialization pathways• Hydrogen is advancing toward defined remote and industrial energy use casesIn this wide ranging discussion, Bernard Tourillon joins usto unpack what management describes as a turning point year. After years of development across three advanced material platforms, the conversation makes clear that HPQ is no longer operating in a purely R&D driven phase.The shift began when HPQ successfully replicated commercial grade fumed silica at pilot scale. That milestone did more than validate the process. It triggered unsolicited outreach from multiple external groups tied to advanced technology infrastructure.Management outlined why fumed silica is increasingly being viewed as a strategic material rather than a niche industrial input. Emerging technology infrastructure requires materials that can withstand higher performance thresholds, and existing supply chains may not be positioned to respond quickly.Today, roughly half of global fumed silica supply is produced in China. At the same time, traditional producers face long construction timelines, complex permitting, and high energy intensity when adding new capacity.HPQ's process takes a different approach by converting quartz directly into fumed silica in a single step. This enables faster permitting, simpler plant construction, and modular expansion once the first commercial facility is built.The company believes this structural advantage could become increasingly relevant if demand accelerates faster than incumbents can scale.On the battery side, HPQ achieved UL 1642 cell level certification, which management repeatedly described as a critical inflection point. Without this certification, customers face barriers related to insurance, transportation, and regulatory compliance.With certification now in place, discussions can move from technical interest to practical execution.According to Tourillon, this allows conversations to advance into customer qualification, volume planning, and partnership structures, particularly in the U.S. market. The company is now developing multiple battery iterations tailored to different performance profiles, including applications such as drones and mobility platforms.Government involvement was also highlighted as a form of validation rather than dependence. Funding is structured to support ongoing scale up as milestones are met, rather than requiring full capital commitment in advance.While hydrogen remains earlier in its commercialization timeline, management emphasized that its role is becoming more concrete. The technology is designed for decentralized energy environments where diesel remains the default option due to logistics and reliability constraints.Examples discussed include northern housing developments, mining camps, and remote industrial sites. HPQ's approach uses recycled aluminum as a stable energy carrier that can be stored indefinitely and activated on demand to produce energy and heat.Tourillon noted that economics and demand visibility are improving, with expectations that early 2026 will begin to demonstrate clearer commercial validation for this platform.One of the most consequential moments in the interview came during a candid discussion about corporate structure. With all three platforms advancing simultaneously, management acknowledged that the current structure may not fully reflect underlying value.“The reality is that the sum of our parts is bigger than the company.”Tourillon confirmed that 2026 is likely the year when formal separation processes begin, with fumed silica identified as the most probable first candidate for independence. The company is already structurally prepared for this outcome through existing subsidiaries.

Today we are joined once more by the renowned herbalist and author Robert Dale Rogers. Known for his extensive research on mushrooms and lichens, Robert is here to discuss the fascinating world of ferns and his latest book, 'The Fern Pharmacy.' We explore the medicinal wonders of ferns, discover their unique lifecycles, and learn some surprising historical and practical uses. Robert shares insights from his journey and research, including the importance of proper preparation for medicinal efficacy and his personal experiences with various fern species. Whether you're an herbalist looking to expand your knowledge or just curious about the hidden potentials of these ancient plants, this episode offers a wealth of information. Stay tuned as Robert also teases his upcoming works on mosses and medicinal cacti. 00:00 Introduction to the Plant Cunning Podcast00:31 Welcoming Robert Dale Rogers01:41 Researching the Fern Pharmacy03:56 Ferns in History and Culture06:30 Medicinal and Edible Ferns17:02 Practical Uses of Ferns20:44 Ferns in Traditional Medicine23:06 Decoctions and Infusions: Using Ferns for Health23:46 Traditional Uses of Ferns in Indigenous Medicine25:15 Favorite Ferns and Their Medicinal Benefits28:24 Ferns in Global Practices and Personal Anecdotes34:37 Silica and Bone Health: The Role of Ferns36:26 Upcoming Projects and Future Research

Nothing says "peace" quite like building a technology bloc. Pax Silica is said to be Washington's "flagship effort on AI and security initiative," which was unveiled at its inaugural summit on December 11, bringing together the U.S., Japan, the Republic of Korea, the UK, Australia, Israel, Singapore, the UAE, and the Netherlands, with others also in the room. What does "Pax Silica" mean? Well, "pax" is Latin for peace while "Silica" refers to silicon. Put together, it sounds like a gift to global coordination, a positive-sum partnership, as the U.S. puts it, which is not about isolating others. But is that really the case?

In this week's episode of The Korea Pro Podcast, Jeongmin, John and Joon Ha examine how economic security, domestic politics and supply-chain strategy are increasingly colliding for South Korea. They begin with the special counsel investigation into former President Yoon Suk Yeol's martial law preparations, discussing why prosecutors concluded the episode was the result of prolonged institutional erosion rather than an isolated abuse of power. The conversation then turns to economic security. The hosts assess the launch of the U.S.-led Pax Silica initiative and Korea Zinc's $7.5 billion U.S. smelter project, focusing on how allied coordination is shifting geopolitical compliance costs onto private firms. They also discuss South Korea's record ICT exports and third-quarter corporate data, unpacking how surging semiconductor shipments to China and rising chaebol profitability are masking deepening stress among small and medium-sized enterprises. The episode concludes with a look ahead to an upcoming ban on the free provision of disposable plastic cups at various business establishments, including cafes, under a comprehensive “de-plastics” policy. About the podcast: The Korea Pro Podcast is a weekly conversation hosted by Korea Risk Group Executive Director Jeongmin Kim, Editor John Lee and correspondent Joon Ha Park, delivering deep, clear analysis of South Korean politics, diplomacy, security, society and technology for professionals who need more than headlines. Uploaded every Friday. This episode was recorded on Thursday, Dec. 18, 2025. Audio edited by Gaby Magnuson

On this episode of Vitality Radio, Jared takes on a fear-based narrative that has been circulating widely in the natural health space—claims that supplements are “toxic,” “fake,” or made from alarming industrial sources. Using vitamin D3 and vitamin K2 as the focal point, Jared breaks down where tiny fragments of truth have been exaggerated into misleading conclusions, and why that kind of half-truth can be more dangerous than an outright lie. If you've ever felt confused or alarmed by supplement claims on social media, this episode will help you develop a more grounded, critical framework—one rooted in physiology, context, and practical application rather than ideology or outrage.Products:Vital D3/K2 High PotencyVital D3/K2Buy D-Mannose Powder and get CranActin FREE ($20 value) - Vitality Radio POW! Product of the Week with PROMO CODE: POW21Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

On this episode of Vitality Radio, Jared continues his deep dive into one of the most overlooked health threats of our time: endocrine-disrupting chemicals. If you haven't listened to Part 1 yet, hit pause and go back — the two episodes build on each other, and the full picture will make far more sense when heard in order.Here, we shift from identifying the problem to showing you how to clear it from your system naturally. This episode breaks down the detoxification phase of the long-awaited Endocrine Detox Protocol — built around four targeted formulas designed to support receptor clearance, liver pathways, gut integrity, and calcium balance to support healthy hormone signaling.If you've been struggling with stubborn symptoms, slow progress, or hormone fluctuations despite “doing everything right,” this episode will help you understand what's been missing — and how to finally address the upstream causes that matter.Products:LiverVitalityEndoCleanseBack On TractVital D3/K2 High PotencyVital D3/K2Magnesium BisglycinateAdditional Information:#588: The Hidden Epidemic Part 1: How Endocrine Disruptors Are Hijacking Your Health#507: Comprehensive Digestive Support to Get Your Gut ‘Back On Tract'!#565: D3, K2, Boron, and Silica: The Ultimate Synergy for Bones, Hormones, Arteries, and More!#258: Your Magnesium User's GuideVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Over the last 15 years, around 1000 New Zealand workers are thought to have been been exposed to high concentrations of respirable crystalline silica dust while working with engineered stone slabs. It's been banned in Australia, and now our government is seeking feedback on options to control the risks it poses in New Zealand. One of the country's largest fabricators has made the switch to zero-silica engineered stone and is now calling on others to do the same. Samantha Gee visited its new factory in Tasman.

Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance, discusses the importance of targeted nutrients for women's health. They delve into various supplements such as magnesium, myo-inositol, progesterone cream, D-Mannose, and biotin, explaining their benefits for conditions like PCOS, blood sugar regulation, menstrual migraines, urinary tract infections, and overall skin, hair, and nail health. The conversation also touches on the importance of tailoring nutrients to individual needs and the role of personalized nutrition in supporting women's health amidst modern stresses.

Dr. Hoffman continues his conversation with Neil Levin, Senior Nutrition Education Manager and product formulator for Now Foods and Protocol for Life Balance.

What happens when the concrete industry's “wonder dust” meets its high-tech rival? In this episode of the Concrete Logic Podcast, host Seth Tandett brings back Dan McCoy and Dr. Jon Belkowitz to challenge everything we thought we knew about silica fume. From bridge deck overlays that crack like eggshells to the real CO₂ math no one wants to talk about, the guys separate hype from chemistry and ask the only question that matters: What are we really asking this concrete to do? What You'll Learn • What is silica fume really — and how did it end up in our concrete? • How does colloidal silica change the way concrete performs in the field? • Why bridge deck overlays using silica fume often fail before their time. • How mix design mistakes turn silica fume into a “volatile” material. • Why colloidal silica can actually cost less than silica fume. • What's the environmental truth behind “green” cement substitutes? • Why performance specifications—not recipes—should drive concrete design. • The one ASTM document every purchaser should actually read. Chapters 00:00 Introduction and Guest Introductions 01:36 Understanding Silica Fume 05:11 Colloidal Silica vs. Silica Fume 13:38 Practical Applications and Challenges 18:34 Cost Analysis and Environmental Impact 32:52 Exploring Concrete Associations and Data Sources 33:07 Understanding CO₂ Emissions in Concrete Materials 34:34 Debating Environmental Impact of Fly Ash 36:03 The Role of Coal in Concrete Production 38:23 Analyzing Silica Fume vs. Colloidal Silica 40:10 Cost and Benefits of Silica in Concrete 41:23 Challenges in Using Silica Fume 43:03 Evaluating Cost Structures of Concrete Materials 45:22 Understanding Concrete Specifications and Purchaser Requirements 46:56 Concluding Thoughts on Concrete Practices Guest Info Dan McCoy, P.E. — R.L. McCoy, Inc. Email: danmccoy@rlmccoy.net LinkedIn: https://www.linkedin.com/in/dan-mccoy-48507730/ Website: https://www.rlmccoy.com Dr. Jon Belkowitz, Ph.D., P.E. — Director of Research, Intelligent Concrete Email: jon.belkowitz@intelligent-concrete.com LinkedIn: https://www.linkedin.com/in/jon-belkowitz-phd-pe-53494719/ Website: https://intelligent-concrete.com Concrete Logic Academy Earn PDHs for courses built from real podcast episodes. Start learning at https://www.concretelogicacademy.com Support the Podcast Donate to keep Concrete Logic independent: https://www.concretelogicpodcast.com/support Shop KUIU gear through our affiliate link: https://www.concretelogicpodcast.com/kuiu For podcast media services or sponsorships: seth@concretelogicpodcast.com Podcast PartnersIntelligent Concrete At Intelligent Concrete, we combine lab precision with field expertise to help you understand what your concrete is telling you. Our services include mix troubleshooting, forensic and petrographic testing, performance-based specification and admixture development, and training for engineers, contractors, and producers. Whether you're chasing consistency, durability, or answers after a failure, Intelligent Concrete delivers the data and insight to solve problems and improve performance. Learn more: https://www.concretelogicpodcast.com/intelligent-concrete Credits Producers: Jodi Tandett & Concrete Logic Media Music by Mike Dunton — https://www.mdunton.com Connectivity Host: Seth Tandett — Concrete Visionary & Host of The #1 Concrete Podcast LinkedIn: https://www.linkedin.com/in/sethtandett YouTube: https://www.youtube.com/@concretelogicpodcast Website: https://www.concretelogicpodcast.com Like, subscribe, comment, and share this episode to help more people think critically about concrete. Let's keep it concrete!

Errol Parker and Effie Bateman wrap up all the biggest stories from the week - live from the Desert Rock FM studio in downtown Betoota. Subscribe to the Betoota Newsletter HERE Betoota on Instagram Betoota on TikTokSee omnystudio.com/listener for privacy information.

What exactly are desiccants, and why are they commonly used in packaging? How does silica gel effectively trap moisture in humid environments? Can you explain the nanoporous structure of silica gel that makes it so efficient? Why do some silica gel packets change color when they reach capacity? Is silica gel really safe to use? Can you reuse them? ... we explain like I'm five. Thank you to the r/explainlikeimfive community and in particular the following users whose questions and comments formed the basis of this discussion: Em_Adespoton, DiamondIceNS, intchd, Gnonthgol, Bosstiality, LCIronmanX, Mr_Automatic, stugautz. To the community that has supported us so far, thanks for all your feedback and comments. Join us on Twitter: https://www.twitter.com/eli5ThePodcast/ or send us an e-mail: ELI5ThePodcast@gmail.com

On this episode of Vitality Radio, we continue our deep dive into systemic enzymes, building on the foundation laid in episodes #530 & 566. This time, the focus is on practical protocols that combine Fibrenza with key companions and targeted nutrient support for cardiovascular health, immune resilience, and recovery. You'll learn how systemic enzymes modulate the immune system for conditions like autoimmune disease and fibromyalgia, why pairing them with other supportive supplements can retrain immune balance and strengthen the gut lining at the root. Jared also shares cardiovascular strategies post-COVID — using Fibrenza with supplements that support nitric oxide, vessel flexibility, and inflammation balance. Finally, the discussion turns to exercise recovery, with protocols designed to accelerate healing, reduce soreness, and protect tendons and ligaments. This episode is about root cause solutions — supporting balance, reducing inflammatory debris, and nourishing the body so it can do what it was designed to do: heal and thrive.Products:Fibrenza Systemic EnzymeKyolic Moducare Daily Immune SupportVital 5 Precision Probiotic Vital SporesNatural Factors L-Glutamine PowderGet Well Stay WellN.O. Cardio BoostVital D3/K2 with Boron & SilicaVital 5 Omega-3 + AntioxidantsNatural Factors Ultra Strength RX Omega-3Omne Diem Connective Tissue TLCTerry Naturally CuraMed Acute PainQueen of the Thrones Castor Oil Eye Mask & Oil (Vitality Radio POW! Product of the Week 30% off both when purchased together with PROMO CODE: POW8)Additional Information:#430: Rebalancing An Overactive Immune System with Jim LaValle#519: Understanding Dairy: Raw vs. Pasteurized with Mark McAfeeRaw-Milk-Facts.com#565: D3, K2, Boron, and Silica: The Ultimate Synergy for Bones, Hormones, Arteries, and More!#530: Systemic Enzymes for Inflammation, Pain, and Heart Health with Mike Kramarczyk#566: Systemic Enzymes for Fibroids, Cysts, Scar Tissue, Autoimmune, and More with Mike Kramarczyk#567: Systemic Enzymes in Action: How to Pair Supplements for Pain, Scar Tissue, Cysts, and Women's Health

On this follow-up to episode #566, Jared takes systemic enzymes one step further by laying out practical protocols for real-life concerns. While the last show explained what systemic enzymes do and why they matter, this episode focuses on how to use them—and how to combine them with other targeted supplements to give the body the tools it need to truly heal rather than just mask symptoms. Jared lays out protocols that address the root causes behind pain and inflammation, and abnormal tissue growth as in scar tissue and adhesions, fibroids, cysts, and endometriosis. If you listened to episode #566 and wanted to know “what do I actually do next?” this show provides the answers with clear, actionable strategies. You'll come away with step-by-step dosing guidelines, companion supplement recommendations, and a roadmap for addressing both symptoms and the root causes behind them. Stay tuned for episode #568 where Jared shares protocols for immune modulation and autoimmune conditions, cardiovascular health, and athletic recovery and performance support!Products:Fibrenza Systemic EnzymeCuramed Acute PainStress & Pain Relief CBD Blend (Phone order only - call 801.292.6662 and mention this episode for $20 off)Solaray Gotu KolaVital D3/K2 with Boron & SilicaLiverVitalityEndoCleanseCastor Oil PacksAdditional Information:#566: Systemic Enzymes for Fibroids, Cysts, Scar Tissue, Autoimmune, and More with Mike Kramarczyk#530: Systemic Enzymes for Inflammation, Pain, and Heart Health with Mike KramarczykVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Host Evie Stokes talks with KEXP DJ Diana Ratsamee about K-pop, the return home of Japanese Breakfast's Michelle Zauner, and her new collaboration with South Korea's Silica Gel on “NamgungFefere.” Zauner released Japanese Breakfast’s latest album For Melancholy Brunettes (& Sad Women) earlier this year on Dead Oceans. Hosted by Evie Stokes. Produced by Lilly Ana Fowler.Mastered by: William MyersProduction support: Serafima HealyAssociate Director of Editorial: Dusty HenryListen to the full songs on KEXP's "In Our Headphones" playlist on Spotify or the “What's In Our Headphones” playlist on YouTube. Support the podcast: kexp.org/headphonesContact us at headphones@kexp.org.Support the show: https://www.kexp.org/donateSee omnystudio.com/listener for privacy information.

On this episode of Vitality Radio, Jared unveils one of most exciting formulas he's ever developed—Vital D3/K2 with Boron and Silica, now available in two optimized potencies. After years of research and formulation, these powerhouse combinations deliver clinically relevant doses of bioavailable vitamin D3, vitamin K2 (as MK7), boron, and silica—all in a single daily capsule. Jared explains why these four ingredients work synergistically to support bone strength, arterial flexibility, hormone balance, detoxification, and even brain function. He discusses why lanolin-based D3 is bioidentical and superior, why 360 mcg of K2 may be the "magic number" for cardiovascular support, and why boron and silica—ignored by the FDA—deserve a place in your daily routine. You'll also hear how to stack these formulas with the Ultimate Vitality Multi for seasonal flexibility and year-round support. If you've ever taken D3 or K2—or thought about starting—don't miss this deep dive into what may be the most complete and cost-effective formulation on the market.Products:Vitality Nutrition Vital D3/K2 with Boron & SilicaVital 5 Magnesium BisglycinateAdditional Information:#315: VR Vintage: Vitamins D3, K2, and Magnesium. What You Need to KnowVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Skin damage and cutaneous wounds can be frustrating and difficult to manage. With a growing world of antibiotic resistance and difficult cases of skin repair, alternative solutions are needed. Zarasyl combines the natural power of silica to optimize the wound healing environment. The product helps to moisturize while being semi-occlusive to allow oxygen through the barrier.Julia Miller, DVM, DACVD is a frequent guest of the podcast and joins once again to discuss her experience with Zarasyl in dogs, cats and horses. This episode provides comedic relief with discussion of being a hand model and Labubus. But, most importantly, you will learn additional ways to treat wounds and manage dermatology cases with Zarasyl.00:00 Intro00:25 Dr. Julia Miller02:16 Zarasyl05:04 Using non-antibiotics when possible07:41 What is Zarasyl?10:54 How and when to use Zarasyl13:20 Can it safely be used long-term?18:04 Top diseases where you're using Zarasyl19:50 Horses22:36 Lessening the duration of antibiotics26:40 Zarasyl's scientific support29:14 Final thoughts about Zarasyl31:58 Outro

This episode originally aired as #304 on 3/1/23. It's an oldie but goodie so we are sharing it again! Collagen is a major buzzword in health and nutrition today. On today's episode Jared provides a precise protocol for preserving and boosting collagen to help you slow and reverse the signs of aging. You'll discover the true value of collagen for appearance, anti-aging, healthy joints, bones, and teeth, and improved gut and microbiome health. For 25% off of the Collagen Trio use promo code: collagen Protocol:Ultimate Vitality Multi - 3/day with breakfastBiosil - 2/day split between two mealsTotal Body Collagen - 1 scoop/day Optional: Anxiety ReleaseAdditional Information:Episode #303: Collagen, How We Make It, Why We Need It, and How to Build More with SilicaEpisode #242: The Vital Five How To: Your User's Guide to Filling the Gaps in Your DietVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.